Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / PharmaResearch Co.,Ltd

Clinicaltrial registered3 Nov 2026

PharmaResearch Co.,Ltd

3 Nov 2026: Trial registered · Clinical Evaluation of Dual-Plane Technique PN-Based Treatment for Horizontal Neck Lines Using DNA Fragment Opmizing Technology Polynucleotide (DOT PN). Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
3 Nov 2026
Title
Clinical Evaluation of Dual-Plane Technique PN-Based Treatment for Horizontal Neck Lines Using DNA Fragment Opmizing Technology Polynucleotide (DOT PN)
Conditions
Skin Aging, Horizontal Neck Lines
Study Type
Observational
Status
Not Yet Recruiting
Countries
Malaysia, Singapore, Thailand
Country
Malaysia
Reference
NCT07912879
Location
Malaysia, Singapore, Thailand
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at PharmaResearch Co.,Ltd

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for PharmaResearch Co.,Ltd in our registers.

More from Malaysia

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.